IRADIMED CORP
IRADIMED Corp (IRMD) is a small-cap medical‑technology company that develops patient temperature‑management systems and MRI‑compatible warming and cooling devices, alongside related consumables. Investors should note the business mixes capital equipment sales with recurring revenue from disposables, so growth depends on both device placements and ongoing consumable uptake. Key drivers include hospital purchasing cycles, clinical adoption, regulatory approvals and reimbursement environments. The company’s roughly $960M market capitalisation reflects market expectations but also exposes it to volatility common in specialised med‑tech names. Risks include competitive pressure from larger device manufacturers, dependence on a limited product range, and the timing of regulatory or procurement events. This summary is for educational purposes only and not personal financial advice; suitability depends on your circumstances and risk tolerance. Values can rise and fall, and past performance is not a guide to future results.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying IRADIMED stock, anticipating it could rise to $99 in value.
Financial Health
IRADIMED CORP shows strong profits and cash flow, indicating solid financial performance and stability.
Dividend
IRADIMED CORP's dividend yield of 0.77% is low, which may not appeal to dividend-seeking investors. If you invested $1000 you would be paid $7.70 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
Abbott
Abbott Laboratories is a global healthcare company that develops and markets a broad range of health care products, including medical devices, diagnostics, nutritionals, and branded generic pharmaceuticals.
AGILENT TECHNOLOGIES INC
Agilent Technologies, Inc. specializes in life sciences, diagnostics and applied markets, providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. The Life Sciences and Diagnostics Markets segment provides contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its services and consumables portfolio in addition to software and laboratory automation solutions, which are designed to improve customer outcomes and represent a range of offerings designed to serve customer needs across end-markets and applications.
ALIGN TECHNOLOGY INC
Align Technology is a medical device company that designs, manufactures and markets a range of dental and orthodontic products.
Baskets Featuring IRMD
Wearable Tech IP Wars: What Investors Should Know
Masimo's lawsuit against U.S. Customs, following a reversal of an import ban on Apple Watches, highlights the fierce competition over intellectual property in wearable health. This theme focuses on the medical technology companies and competitors poised to benefit from the ongoing patent battles in the lucrative health-monitoring device market.
Published: August 21, 2025
Explore BasketImmersive Rehab & VR Therapy
Virtual and augmented reality are transforming healthcare with innovative digital treatments for physical and psychological healing. These carefully selected companies are at the forefront of creating immersive technologies that offer effective alternatives to traditional therapies, poised to benefit from growing clinical acceptance.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Patient temperature tech
Focuses on warming and cooling systems and MRI‑compatible devices; recurring consumables can support revenue, though adoption and reimbursement affect outcomes.
Hospital adoption trends
Sales depend on hospital purchasing cycles, clinical guidelines and training; growth can be uneven as hospitals prioritise budgets.
Regulatory & competitive
Subject to FDA and international approvals and competition from larger med‑tech firms; regulatory setbacks or competitive wins can materially impact performance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
